BioSyent approves grant of 56,767 Restricted Share Units, focusing on healthcare products

From GlobeNewswire: 2025-03-18 16:40:05

BioSyent Inc. has approved a grant of 56,767 Restricted Share Units to directors, officers, and employees, vesting in three years. The company, listed on the TSX Venture Exchange under “RX”, focuses on in-licensing or acquiring healthcare products. With 11,262,517 common shares outstanding, BioSyent supports healthcare professionals through marketing. For more information, visit www.tmxmoney.com or contact President and CEO, Mr. René C. Goehrum. This press release warns of potential risks, including those related to clinical trials and regulatory approvals. TSX Venture Exchange does not endorse the accuracy of this release.



Read more at GlobeNewswire: BioSyent Announces Grant of Restricted Share Units